Shares of Aptevo Therapeutics Inc (NASDAQ:APVO) have been assigned an average broker rating score of 1.00 (Strong Buy) from the two analysts that provide coverage for the stock, Zacks Investment Research reports. Two investment analysts have rated the stock with a strong buy rating.

Brokers have set a 12 month consensus price target of $11.50 for the company and are predicting that the company will post ($0.59) earnings per share for the current quarter, according to Zacks. Zacks has also assigned Aptevo Therapeutics an industry rank of 80 out of 255 based on the ratings given to its competitors.

A number of brokerages recently issued reports on APVO. Zacks Investment Research upgraded shares of Aptevo Therapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday, July 24th. Piper Jaffray Companies restated an “overweight” rating and issued a $11.00 price target on shares of Aptevo Therapeutics in a research note on Friday, August 10th. Finally, ValuEngine lowered shares of Aptevo Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, July 24th.

Several large investors have recently modified their holdings of the stock. Dimensional Fund Advisors LP increased its stake in Aptevo Therapeutics by 10.8% during the second quarter. Dimensional Fund Advisors LP now owns 1,351,656 shares of the biotechnology company’s stock valued at $6,745,000 after purchasing an additional 131,804 shares during the last quarter. Renaissance Technologies LLC increased its stake in Aptevo Therapeutics by 53.3% during the second quarter. Renaissance Technologies LLC now owns 1,149,400 shares of the biotechnology company’s stock valued at $5,736,000 after purchasing an additional 399,400 shares during the last quarter. Acadian Asset Management LLC increased its stake in Aptevo Therapeutics by 79.0% during the second quarter. Acadian Asset Management LLC now owns 367,509 shares of the biotechnology company’s stock valued at $1,833,000 after purchasing an additional 162,218 shares during the last quarter. JPMorgan Chase & Co. increased its stake in Aptevo Therapeutics by 346.6% during the first quarter. JPMorgan Chase & Co. now owns 254,282 shares of the biotechnology company’s stock valued at $832,000 after purchasing an additional 197,341 shares during the last quarter. Finally, Park West Asset Management LLC bought a new stake in Aptevo Therapeutics during the first quarter valued at $604,000. Institutional investors and hedge funds own 33.08% of the company’s stock.

Shares of NASDAQ:APVO opened at $4.26 on Friday. The company has a debt-to-equity ratio of 0.27, a current ratio of 3.66 and a quick ratio of 3.50. The firm has a market capitalization of $115.16 million, a P/E ratio of -2.78 and a beta of 0.79. Aptevo Therapeutics has a 12-month low of $2.25 and a 12-month high of $6.35.

Aptevo Therapeutics (NASDAQ:APVO) last issued its quarterly earnings results on Thursday, August 9th. The biotechnology company reported ($0.58) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.65) by $0.07. The business had revenue of $6.83 million during the quarter, compared to analyst estimates of $4.17 million. Aptevo Therapeutics had a net margin of 74.01% and a negative return on equity of 45.53%. Equities research analysts predict that Aptevo Therapeutics will post -2.41 earnings per share for the current year.

About Aptevo Therapeutics

Aptevo Therapeutics Inc, a biotechnology company, engages in the discovery, development, commercialization, and sale of novel oncology and hematology therapeutics in the United States. Its marketed products include IXINITY, which is indicated in adults and children 12 years of age and older with hemophilia B for control and prevention of bleeding episodes, and management of bleeding during operations; and WinRho SDF for the treatment of autoimmune platelet disorders, as well as for the treatment of hemolytic disease of the newborn.

Recommended Story: Analyst Ratings

Get a free copy of the Zacks research report on Aptevo Therapeutics (APVO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Aptevo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptevo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.